Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers

European Journal of Heart Failure

Volumn 12, Issue 4, 2010, Pages 404-410

  Bergh, Claes Hkan ^a   Andersson, Bert ^a   Dahlström, Ulf ^b   Forfang, Kolbjorn ^c   Kivikko, Matti ^d   Sarapohja, Toni ^d   Ullman, Bengt ^e   Wikström, Gerhard ^f  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d R and D Orion Pharma ^*  (Finland)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Decompensated heart failure; Dobutamine; Invasive monitoring; Levosimendan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; LEVOSIMENDAN; PLACEBO;

ACUTE HEART FAILURE; AGED; ARTICLE; CARDIAC PATIENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART RATE; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPOKALEMIA; HYPOTENSION; INSOMNIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT MONITORING; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; CONFIDENCE INTERVALS; DOBUTAMINE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYDRAZONES; MALE; MYOCARDIAL PERFUSION IMAGING; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PERFUSION; PULMONARY WEDGE PRESSURE; PYRIDAZINES; VASODILATOR AGENTS;

EID: 77950251147     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq032     Document Type: Article

References (16)

1. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-1866.
2. Yildiz O. Vasodilating mechanisms of levosimendan: involvement of K\+ channels. J Pharmacol Sci 2007;104:1-5.
3. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Na°gren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during levosimen-dan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-531.
4. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912.
5. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102:2222-2227.
6. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
7. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891.
8. Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009;11:304-311.
9. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levo-simendan and its metabolites during and after a 24 h continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-471.
10. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107:81-86.
11. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J 1964;2:177.
12. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing. Biometrika 1988;75:800-803.
13. Bollano E, Scharin Täng M, Hjalmarson A, Waagstein F, Andersson B. Different response to dobutamine in presence of carvedilol or metoprolol in patients with chronic heart failure. Heart 2003;89:621-624.
14. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007;9:75-82.
15. Teng JK, Kwan CM, Lin LJ, Tsai LM, Cheng JT, Chang WC, Chen JH. Down-regulation of beta-adrenergic receptors on mononuclear leukocytes induced by dobutamine treatment in patients with congestive heart failure. Eur Heart J 1993;14:1349-1353.
16. Unverferth DA, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 h continuous infusion. Am J Med 1980;69:262-266.